A phase 2 trial Evaluating Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma
Latest Information Update: 09 Jul 2024
At a glance
- Drugs SHR-2554 (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 09 Jul 2024 New trial record
- 04 Jun 2024 Primary end point (progression-free rate at 12 weeks) has been met, according to a results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology